DE602007010303D1 - Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen - Google Patents
Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomenInfo
- Publication number
- DE602007010303D1 DE602007010303D1 DE602007010303T DE602007010303T DE602007010303D1 DE 602007010303 D1 DE602007010303 D1 DE 602007010303D1 DE 602007010303 T DE602007010303 T DE 602007010303T DE 602007010303 T DE602007010303 T DE 602007010303T DE 602007010303 D1 DE602007010303 D1 DE 602007010303D1
- Authority
- DE
- Germany
- Prior art keywords
- dion
- isoindol
- climb
- piperidine
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83575206P | 2006-08-03 | 2006-08-03 | |
PCT/US2007/017343 WO2008019065A1 (en) | 2006-08-03 | 2007-08-02 | Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602007010303D1 true DE602007010303D1 (de) | 2010-12-16 |
Family
ID=38691762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602007010303T Active DE602007010303D1 (de) | 2006-08-03 | 2007-08-02 | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen |
Country Status (26)
Country | Link |
---|---|
US (7) | US20080038263A1 (de) |
EP (1) | EP2046331B1 (de) |
JP (2) | JP5465005B2 (de) |
KR (2) | KR101483802B1 (de) |
CN (2) | CN101583359B (de) |
AR (1) | AR062265A1 (de) |
AT (1) | ATE486601T1 (de) |
AU (1) | AU2007282027B2 (de) |
CA (2) | CA2659774C (de) |
CL (1) | CL2007002218A1 (de) |
CY (1) | CY1110989T1 (de) |
DE (1) | DE602007010303D1 (de) |
DK (1) | DK2046331T3 (de) |
ES (1) | ES2351069T3 (de) |
HR (1) | HRP20100664T1 (de) |
IL (1) | IL196885A (de) |
ME (1) | ME01937B (de) |
MX (1) | MX2009001268A (de) |
PE (1) | PE20081311A1 (de) |
PL (1) | PL2046331T3 (de) |
PT (1) | PT2046331E (de) |
RS (1) | RS51567B (de) |
RU (1) | RU2446804C2 (de) |
SI (1) | SI2046331T1 (de) |
TW (1) | TWI430797B (de) |
WO (1) | WO2008019065A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
MX2010009344A (es) * | 2008-03-11 | 2012-09-28 | Reddys Lab Ltd Dr | Preparacion de lenalidomida. |
US20110280913A1 (en) * | 2008-07-31 | 2011-11-17 | The Ohio State University | Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders |
JP2013522236A (ja) * | 2010-03-12 | 2013-06-13 | セルジーン コーポレイション | レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー |
BR112014026957A8 (pt) | 2012-05-03 | 2018-01-16 | Janssen R&D Ireland | micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior |
CN104004056B (zh) * | 2014-06-23 | 2016-08-17 | 王方杰 | 一种关于Cyclin D蛋白抑制剂多肽及其应用 |
CN104031122B (zh) * | 2014-06-23 | 2016-05-11 | 常州市肿瘤医院 | 有关Cyclin D蛋白抑制剂多肽及其应用 |
CN104004060B (zh) * | 2014-06-23 | 2016-04-13 | 重庆医科大学 | Cyclin D蛋白抑制剂多肽及其应用 |
US11034667B2 (en) | 2017-01-09 | 2021-06-15 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
CA3087565A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
EP3781156A4 (de) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | Spirocyclische verbindungen |
EP3846800A4 (de) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Verbindungen zum abbau von brd9 oder mth1 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
EP3935050A4 (de) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | Heterocyclische verbindungen zur medizinischen behandlung |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5A (en) * | 1836-08-10 | Thomas blancharjq | ||
US2845770A (en) * | 1956-09-26 | 1958-08-05 | William F Fessler | Baled hay rack and carrier |
US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3636809A (en) * | 1969-07-10 | 1972-01-25 | Nippon Musical Instruments Mfg | Stringed musical instrument |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
DE69717831T3 (de) | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
DE69720735T9 (de) * | 1996-08-12 | 2005-08-25 | Celgene Corp. | Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte |
ATE305301T1 (de) * | 1996-11-05 | 2005-10-15 | Childrens Medical Center | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
CN100390163C (zh) * | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途 |
US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
ES2250121T3 (es) * | 1999-03-18 | 2006-04-16 | Celgene Corporation | 1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias. |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
TR200202194T2 (tr) | 2000-03-17 | 2003-01-21 | Cell Therapeutics, Inc. | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri |
MXPA02009665A (es) * | 2000-03-31 | 2005-09-08 | Celgene Corp | Inhibicion de actividad de ciclooxigenasa-2. |
JP5409981B2 (ja) * | 2000-05-15 | 2014-02-05 | セルジーン コーポレイション | 癌治療用の組成物および方法 |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (de) | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
WO2002068414A2 (en) * | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
JP4494013B2 (ja) * | 2001-08-06 | 2010-06-30 | ザ チルドレンズ メディカル センター コーポレイション | 窒素置換サリドマイド誘導体の合成及び抗腫瘍活性 |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
JP2005536189A (ja) | 2002-04-12 | 2005-12-02 | セルジーン・コーポレーション | 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法 |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CN1697655B (zh) * | 2002-05-17 | 2013-09-18 | 细胞基因公司 | 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物 |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
CL2004001004A1 (es) * | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
US7893045B2 (en) * | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
-
2007
- 2007-07-31 CL CL200702218A patent/CL2007002218A1/es unknown
- 2007-08-01 US US11/888,881 patent/US20080038263A1/en not_active Abandoned
- 2007-08-01 TW TW096128250A patent/TWI430797B/zh active
- 2007-08-02 KR KR1020097004393A patent/KR101483802B1/ko not_active IP Right Cessation
- 2007-08-02 RS RS20100541A patent/RS51567B/en unknown
- 2007-08-02 WO PCT/US2007/017343 patent/WO2008019065A1/en active Application Filing
- 2007-08-02 CA CA2659774A patent/CA2659774C/en active Active
- 2007-08-02 SI SI200730446T patent/SI2046331T1/sl unknown
- 2007-08-02 DE DE602007010303T patent/DE602007010303D1/de active Active
- 2007-08-02 CN CN200780036550.7A patent/CN101583359B/zh active Active
- 2007-08-02 ES ES07811048T patent/ES2351069T3/es active Active
- 2007-08-02 KR KR1020147014837A patent/KR20140082859A/ko not_active Application Discontinuation
- 2007-08-02 RU RU2009107535/15A patent/RU2446804C2/ru not_active IP Right Cessation
- 2007-08-02 ME MEP-2010-541A patent/ME01937B/me unknown
- 2007-08-02 AT AT07811048T patent/ATE486601T1/de active
- 2007-08-02 PT PT07811048T patent/PT2046331E/pt unknown
- 2007-08-02 CN CN2012103235264A patent/CN102908346A/zh active Pending
- 2007-08-02 DK DK07811048.3T patent/DK2046331T3/da active
- 2007-08-02 JP JP2009522882A patent/JP5465005B2/ja active Active
- 2007-08-02 CA CA2836006A patent/CA2836006A1/en not_active Abandoned
- 2007-08-02 PL PL07811048T patent/PL2046331T3/pl unknown
- 2007-08-02 EP EP07811048A patent/EP2046331B1/de active Active
- 2007-08-02 AU AU2007282027A patent/AU2007282027B2/en active Active
- 2007-08-02 MX MX2009001268A patent/MX2009001268A/es active IP Right Grant
- 2007-08-03 AR ARP070103447A patent/AR062265A1/es unknown
- 2007-08-03 PE PE2007001016A patent/PE20081311A1/es not_active Application Discontinuation
-
2009
- 2009-02-03 IL IL196885A patent/IL196885A/en active IP Right Grant
- 2009-11-19 US US12/621,502 patent/US8741929B2/en active Active
-
2010
- 2010-12-02 HR HR20100664T patent/HRP20100664T1/hr unknown
- 2010-12-10 CY CY20101101137T patent/CY1110989T1/el unknown
-
2013
- 2013-08-15 JP JP2013168932A patent/JP2013256514A/ja not_active Withdrawn
-
2014
- 2014-05-30 US US14/291,364 patent/US20140271638A1/en not_active Abandoned
-
2016
- 2016-06-09 US US15/178,440 patent/US20170027923A1/en not_active Abandoned
-
2018
- 2018-05-18 US US15/984,018 patent/US20180263968A1/en not_active Abandoned
-
2019
- 2019-08-21 US US16/546,983 patent/US20190374529A1/en not_active Abandoned
-
2020
- 2020-05-13 US US15/930,845 patent/US20200276175A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602007010303D1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
ATE550329T1 (de) | Heterobicyclische sulfonamidderivate zur behandlung von diabetes | |
ATE521365T1 (de) | Kinin-antagonisten zur behandlung von blasenfunktionsstörung | |
ATE516286T1 (de) | 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes | |
DE602005026984D1 (de) | Chinolin-derivate zur behandlung von latenter tuberkulose | |
DE602005015577D1 (de) | Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
DE602006010243D1 (de) | 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen | |
ATE527241T1 (de) | Pyridiazinonderivate zur behandlung von tumoren | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
ATE512948T1 (de) | Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen | |
IL190437A0 (en) | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias | |
ATE505468T1 (de) | N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden | |
EA200971077A1 (ru) | Гетероциклические модуляторы киназы | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
ATE486597T1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
ATE493986T1 (de) | Diarylharnstoffe zur behandlung von pulmonaler hypertonie | |
DK2300443T3 (da) | Triazolderivater, der er anvendelige til behandling af sygdomme | |
ATE538114T1 (de) | 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten | |
ATE534633T1 (de) | Indazolderivate zur behandlung von hsp90- induzierten krankheiten | |
DK2041093T3 (da) | Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer | |
DK2010184T3 (da) | Implatanter til behandlingen af dopamin associerede tilstande | |
DE602006010449D1 (de) | Behandlung von geflügel zwecks reduzierung der futon ascites | |
DE602007011398D1 (de) | Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen | |
PL2310043T3 (pl) | Czynnik von Willebranda lub czynnik VIII i czynnik von Willebranda do leczenia koagulopatii wywołanej inhibitorami trombocytów | |
DE602006017367D1 (de) | Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut |